
Aarti Drugs Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-08-05 08:03:57Aarti Drugs Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a modest day gain of 1.77%, the small-cap pharmaceutical company faces a challenging outlook as its MarketsMOJO grade was downgraded from Hold to Sell on 21 May 2026, underscoring caution among investors amid mixed technical indicators and underwhelming long-term returns compared to the broader Sensex.
Read full news article
Aarti Drugs Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
2026-08-04 08:06:03Aarti Drugs Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Despite some bullish signals on weekly indicators, the overall technical landscape suggests caution for investors as the stock faces downward pressure amid a recent downgrade in its mojo grade to Sell.
Read full news article
Aarti Drugs Q1 FY27: Modest Growth Masks Margin Resilience Amid Profitability Pressures
2026-08-01 13:17:59Aarti Drugs Ltd., a prominent manufacturer of active pharmaceutical ingredients (APIs) and pharma intermediates, reported consolidated net profit of ₹50.17 crores for Q1 FY27 (June 2026 quarter), marking a decline of 9.10% quarter-on-quarter from ₹55.19 crores in Q4 FY26 and a 6.94% drop year-on-year from ₹53.91 crores in Q1 FY26. The ₹3,854-crore market capitalisation company faced headwinds from sequential profit compression despite maintaining operational margin discipline, with the stock trading at ₹423.50 as of July 31, 2026, reflecting a modest 2.64% gain on the day following the results.
Read full news article
Aarti Drugs Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-07-30 08:01:37Aarti Drugs Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a modest day gain of 1.41%, the stock’s technical profile and recent rating downgrade to a Sell by MarketsMOJO highlight a cautious outlook for investors navigating the Pharmaceuticals & Biotechnology sector.
Read full news article
Aarti Drugs Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
2026-07-29 08:02:22Aarti Drugs Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite some bullish weekly signals, monthly indicators suggest caution, reflecting a complex interplay of market forces and investor sentiment as the stock trades at ₹407.25, down 0.92% from the previous close.
Read full news article
Aarti Drugs Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-07-28 08:03:15Aarti Drugs Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across key technical indicators. Despite a modest day gain of 1.58%, the stock’s broader technical picture remains mixed, with divergent signals from MACD, RSI, moving averages, and other momentum oscillators, underscoring the need for cautious investor appraisal.
Read full news article
Aarti Drugs Ltd is Rated Sell
2026-07-27 10:10:55Aarti Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 27 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news article
Aarti Drugs Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
2026-07-23 08:02:39Aarti Drugs Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with recent indicators signalling a transition from sideways to mildly bearish trends. Despite some bullish weekly signals, the overall technical landscape suggests caution for investors as the stock faces downward pressure amid broader market challenges.
Read full news article
Aarti Drugs Ltd is Rated Sell
2026-07-16 10:11:13Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 July 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news articleAarti Drugs Limited - Disclosure under SEBI Takeover Regulations
22-Nov-2019 | Source : NSEDisclosure under SEBI Takeover Regulations AARTIDRUGS : Seema Harshit Savla has submitted to the Exchange, vide letter dated November 21, 2019 a copy of disclosure under Regulation 10(6) in respect of acquisition under Regulation 10 of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
Aarti Drugs Limited - Acquisition
21-Nov-2019 | Source : NSEAarti Drugs Limitedany namely Aarti Speciality Chemicals Limited CIN No: U24230MH2019PLC333306 on November 20, 2019.
Aarti Drugs Limited - Disclosure under SEBI Takeover Regulations
08-Nov-2019 | Source : NSEDisclosure under SEBI Takeover Regulations AARTIDRUGS : Seema Harshit Savla has submitted to the Exchange vide letter dated November 07, 2019 a copy of Disclosure as per Regulation 10(5) of SEBI (SAST) Regulation 2011
Corporate Actions
No Upcoming Board Meetings
Aarti Drugs Ltd has declared 20% dividend, ex-date: 09 Feb 26
No Splits history available
Aarti Drugs Ltd has announced 3:1 bonus issue, ex-date: 30 Sep 20
No Rights history available






